Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
3.260
-0.220 (-6.32%)
At close: Oct 13, 2025, 4:00 PM EDT
3.270
+0.010 (0.31%)
After-hours: Oct 13, 2025, 5:23 PM EDT
Alaunos Therapeutics Revenue
Alaunos Therapeutics had revenue of $6.00K in the twelve months ending June 30, 2025, down -14.29% year-over-year. In the year 2024, Alaunos Therapeutics had annual revenue of $10.00K with 100.00% growth.
Revenue (ttm)
$6.00K
Revenue Growth
-14.29%
P/S Ratio
1,172.71
Revenue / Employee
$6,000
Employees
1
Market Cap
7.31M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.00K | 5.00K | 100.00% |
Dec 31, 2023 | 5.00K | -2.92M | -99.83% |
Dec 31, 2022 | 2.92M | 2.52M | 634.17% |
Dec 31, 2021 | 398.00K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TCRT News
- 4 months ago - Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - GlobeNewsWire
- 5 months ago - PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) - GlobeNewsWire
- 2 years ago - Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - GlobeNewsWire
- 2 years ago - Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS) - Benzinga
- 2 years ago - Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives - GlobeNewsWire
- 2 years ago - Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies - GlobeNewsWire
- 2 years ago - Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting - GlobeNewsWire
- 2 years ago - Alaunos Therapeutics, Inc. (TCRT) Q1 2023 Earnings Call Transcript - Seeking Alpha